Health Care Equipment & Services

Definitive Healthcare insider sales reveal tax‑planning moves amid a 6% month‑to‑date drop, yet the company’s data‑driven health‑tech model and expanding payer contracts could cushion the decline and sustain long‑term growth.

Certara insider buy: modest 14,510 shares, signals confidence amid steep price drop, regulatory delays, and cloud‑shift opportunity.

Insider buying at Zimmer Biomet Holdings shows senior execs backing a “buy‑the‑dip” strategy, hinting at potential upside as the company pushes its orthopedic pipeline.

Teladoc insider trades reveal steady RSU conversions amid a weak market; executives keep holdings while managing tax needs, hinting at long‑term confidence despite falling stock price.

Shetty Sanjay K’s recent Humana insider trades show steady growth and risk‑managed confidence in the company’s Medicare Advantage strategy.

Insider Okamoto’s zero‑cost option grant signals Axe Compute’s shift toward AI‑powered oncology, backing a 152% share rally and a $12 M pipeline—can the firm hit its $7.5 M revenue target?

Explore how Hinge Health’s insider buy signals confidence, its digital‑therapy growth strategy, and outcome‑based reimbursement impact on investors.

Insider buying sprees at Vivos Therapeutics signal confidence amid volatility: insiders bought 1.045M shares and 2.713M warrants at $1.34, hinting at a potential rebound.

Phreesia’s insider buying by Pale Fire Capital signals a value‑driven bet amid regulatory shifts, low P/E, and a chance to capitalize on telehealth growth.

Insider buying at Establishment Labs Holdings shows executive confidence amid market swings—learn how ELHI’s regulatory strengths and growth strategy could boost future returns.